Matthew Siegel

Matthew Siegel's work experience begins in 2002 when they started as a Graduate Student at Stanford University, where they focused on evaluating potential therapeutics for treating celiac disease. Matthew developed in vitro, cell culture, and in vivo assays to assess the efficacy of gluten specific proteases and chemically modified, synthetic peptides for destroying immunogenic gluten peptides and blocking T cell recognition.

From 2007 to 2013, Siegel worked at Alvine Pharmaceuticals Inc as a Senior Scientist. Matthew contributed to drug development for celiac disease, including assay development (ELISA, T cell, enzyme activity assays, HPLC), protease discovery, translational research, and formulation development. Matthew played a role in the successful Phase 2a clinical trial and made discoveries leading to patents in protease stability and activity.

Next, from 2013 to 2018, Siegel worked at Ardelyx in various positions, including Director of Cellular and Molecular Pharmacology. In this role, they established an intestinal epithelial stem cell monolayer platform to support drug discovery and development, identified a novel mechanism for enhancing potassium secretion into the colon, managed a group of cell biologists and biochemists, and provided in vitro biology and translational biology support for drug discovery programs.

From 2018 to 2021, Siegel served as the Vice President of Research at Anwita Biosciences. Details about their specific responsibilities and accomplishments during this time are not provided.

Most recently, in 2021, Siegel became the Senior Director of Translational Research at CARGO Therapeutics, although no additional information about this role is provided.

Matthew Siegel earned their Ph.D. from Stanford University, where they attended from 2002 to 2007. Prior to that, they obtained their Bachelor of Science degree in Chemical Engineering from the University of Notre Dame, which they completed between 1998 and 2002.